modelJ05AH01
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Zanamivir | |
| ATC code: | J05AH01 | route: | inhalation |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 16.7 | L |
| clearance: | 2.5 | L/h |
| other parameters in model implementation | ||
Zanamivir is a neuraminidase inhibitor antiviral drug used to treat and prevent influenza A and B. It is administered by inhalation and is currently approved for clinical use in many countries.
Pharmacokinetics
Reported pharmacokinetic parameters in healthy adult volunteers after inhaled administration.
References
Zuo, P, et al., & Hossain, M (2020). Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza. Clinical and translational science 13(1) 157–168. DOI:10.1111/cts.12697 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31664778
Yoshihara, K, et al., & Kubo, Y (2013). Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection. Drug metabolism and pharmacokinetics 28(5) 416–426. DOI:10.2133/dmpk.dmpk-12-rg-115 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23574886
Peng, AW, et al., & Moore, KH (2000). A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. Journal of clinical pharmacology 40(3) 242–249. DOI:10.1177/00912700022008900 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10709152
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)